Delfi Diagnostics

Test Performance

Key Features

Lung cancer blood test • Fragmentomics technology • Complements low-dose CT • For lung-screening-eligible adults

Who It's For

Suited to: Adults 50-80 with a 20 pack-year smoking history, alongside low-dose CT

Not suited to: People not eligible for lung cancer screening; it does not replace low-dose CT

Important Notes

Novel fragmentomics approach - applies machine learning to whole-genome sequencing of cfDNA fragmentation patterns. Complements rather than replaces low-dose CT screening. 99.8% negative predictive value; an elevated result raises the likelihood of finding lung cancer on LDCT by 5.2x. For adults 50-80 with a 20 pack-year smoking history. CLIA LDT, not FDA approved. Now authorised in all 50 states following its New York State permit in 2026.